Company intelligence / Profile preview
IDEC Pharmaceuticals
San Francisco, California, United States
- Ownership
- Private
- Development stage
- Other
01
Overview
IDEC Pharmaceuticals developed Rituxan (rituximab), the first monoclonal antibody approved for cancer (B-cell non-Hodgkin's lymphoma in 1997), and Zevalin (ibritumomab tiuxetan), approved in 2002. Additional products included Amevive for psoriasis.[1][2]
- Therapeutic areas
- OncologyImmunologyDermatology
- Modalities
- Monoclonal antibodyRadioimmunotherapy
- Industry
- Pharma
02
Drug pipeline
11 assets10 more assets in the full pipeline.
Request access →03
Partnerships
Genentech
Beyond the preview
Go deeper on IDEC Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IDEC Pharmaceuticals.